Summit Therapeutics Announces PhaseOut DMD Did Not Meet Primary Endpoint
We are disappointed to learn that Summit Therapeutics plc today announced that their PhaseOut DMD trial has not met its primary or secondary endpoints after 48 weeks of treatment of ezutromid in patients with Duchenne….Learn More
